Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 8Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Male Urogenital Diseases 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Genital Diseases, Male 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasm Malignant Female 1Advanced Cancer 1

Interventions

padeliporfin 4darolutamide 2apalutamide 2Abiraterone Acetate 2palladium-bacteriopheophorbide 1onapristone 1niraparib 1ixabepilone 1gedatolisib 1gallium 68 PSMA-11 1enzalutamide 1abiraterone 1Therapeutics 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Imatinib Mesylate 1EPI-506 1Docetaxel 1BAY 86-7548 1Androgen Antagonists 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Diseases, Male × gedatolisib × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡